Please assess the completion status of the following clinical trial:

Trial Title: Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult males and females ≥18 years~* Existing diagnosis of COPD for \>6 months~* Chronic productive cough~* Radiographic evidence of flattening of the diaphragm~* Prior COVID-19 diagnosis~* Clinically followed by Mount Sinai COVID-19 Post Recovery and Respiratory Institute.~* Ability to provide informed consent~* Ability to read and fill out survey questionnaires via REDCap (surveys will be available in English and Spanish)~* Access to a home computer, tablet, or smartphone~Exclusion Criteria:~* Presenting with hypoxia (02 sat \<90%)~* Acute COVID-19 infection~* Home oxygen dependent~* Established diagnosis of cystic fibrosis~* History of osteoporosis or rib fracture~* Active Hemoptysis~* Pneumothorax

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Care Plus Monitoring (Type: ACTIVE_COMPARATOR): All subjects will be monitored via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.
- Standard Care Plus Monitoring and HCFWO (Type: EXPERIMENTAL): In addition to home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments, subject will receive an Afflovest device for home use.

Based on this trial design, predict the completion outcome and termination type (if applicable).